TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06028321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group F (Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group G ( Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT05183152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES Feedback
Description: Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Feedback
Description: Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Feedback
Description: Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESS
Description: Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
Study: NCT06359106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 80% Oxygen
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40% Oxygen
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
Study: NCT05391516

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of shoulder problems
Description: The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
Study: NCT04670887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed surgery
Description: Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate surgery
Description: Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
Study: NCT05308069

Intervention type: DEVICE
Group type: OTHER
Intervention: Single vision contact lens
Description: Subjects will wear a single vision soft contact lens only during the study visit

Intervention type: DEVICE
Group type: OTHER
Intervention: Multifocal contact lens
Description: Subjects will wear a multifocal soft contact lens only during the study visit
Study: NCT05875987

Intervention type: DEVICE
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT05293912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG2501
Description: During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
Study: NCT06473077

Intervention type: PROCEDURE
Intervention: ETT beyond C7 level
Description: Endotracheal cuff is placed deeper beyond C7 level, but above carina
Study: NCT05243784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-HIIT intervention
Description: Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities.
Study: NCT05692817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound
Description: The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol.
Study: NCT05736042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens fragmentation
Description: Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
Study: NCT06335160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
Study: NCT06217640

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual X Ray Absorptiometry
Description: * Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual X Ray Absorptiometry
Description: * Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength
Study: NCT02930811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg oral morning dose
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral morning dose
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Study: NCT05228028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca compartement block
Description: Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
Study: NCT05801250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI Platform
Description: AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
Study: NCT06241872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling group
Description: Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dry needling group
Description: Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
Study: NCT05039138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEUROMUSCULAR TRAINING EXERCISE
Description: patients will receive neuromuscular training exercises in group II
Study: NCT06398600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal
Description: In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
Study: NCT05039138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional training exerises
Description: traditional strength training exercises in group I
Study: NCT03496610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivicaine
Description: Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Patient will receive ultrasound guided QL Block
Study: NCT06321887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)
Description: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)
Description: Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)
Description: Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
Study: NCT05886829

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine Maleate 0.4% Nasal Spray
Description: Chlorpheniramine Maleate 0.4% Nasal Spray
Study: NCT06505941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: umbilical cord mesenchymal stem cell

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-cell-containing placebo
Study: NCT05252598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inonotus Obliquus Whole Extract
Description: 1mg encapsulated chaga mushroom
Study: NCT05776251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold.
Study: NCT06353711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CA-LINC Intervention
Description: Participants received the CA-LINC intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants received Treatment as Usual
Study: NCT05540028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25
Description: 25 valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: 20 valent pneumococcal conjugate vaccine
Study: NCT05487534

Intervention type: OTHER
Intervention: Observational
Description: The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.

Intervention type: OTHER
Intervention: Observational
Description: The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
Study: NCT05202730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New local anesthesia injection site and new local anesthetic drug formulation.
Description: The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New local anesthesia injection site and new local anesthetic drug formulation.
Description: The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New local anesthesia injection site and new local anesthetic drug formulation.
Description: The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: New local anesthesia injection site and new local anesthetic drug formulation.
Description: The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
Study: NCT06032650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics exercise and High intensity interval training
Description: 1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics exercise and High intensity interval training
Description: 1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax
Study: NCT04889287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Once daily over 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single doses on Day 1, Day 8, and Day 13
Study: NCT06171724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shoden 240 mg
Description: Participants will receive a single dose of 240 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 240 mg per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Shoden 480 mg
Description: Participants will receive a single dose of 480 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 480 mg per day.
Study: NCT04987385

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Protein supplementation
Description: Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral urea
Description: Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, ...) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
Study: NCT05734430

Intervention type: GENETIC
Intervention: Genetic profiling
Description: Whole exome sequencing

Intervention type: GENETIC
Intervention: Genetic profiling
Description: Whole exome sequencing

Intervention type: GENETIC
Intervention: Genetic profiling
Description: Whole exome sequencing

Intervention type: OTHER
Intervention: Retrospective tissue procurement
Description: Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed

Intervention type: OTHER
Intervention: Retrospective tissue procurement
Description: Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
Study: NCT05886829

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT06122376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-shaped Power Toothbrush
Description: Twice daily brushing for 30 seconds with fluoride toothpaste

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Soft Manual Toothbrush
Description: Twice daily brushing for two minutes with fluoride toothpaste
Study: NCT06398600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum plane block
Description: The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
Study: NCT05618951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Trapezius Strengthening Exercises
Description: Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra
Study: NCT05209152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered as an IV infusion or subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered as an IV infusion or subcutaneous (SC) injection.